Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

Oramed Pharmaceuticals Reports Positive Results From A Study Of Oral Insulin Capsule On Type 1 Diabetic Patients
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed"s first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed"s trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients.
buy viagra
Budget Cuts For Minnesota Health Care Programs, Again
Minnesota Gov. Tim Pawlenty, R-Minn., announced Tuesday that "health and human services will come in for $236 million in additional cuts as part of his unallotment strategy," the Star Tribune reports. The "list of about 20 cuts to health services" includes ending a health care program for the poor "six weeks sooner than expected, saving $15 million" and "reducing hours for personal care attendants, who serve fragile and disabled people." Pawlenty "noted he was proposing no new payment reductions for primary care doctors and clinics, and no additional cuts in Medicaid reimbursements to hospitals that serve a large number of poor patients."
News of the day
August 1-7, 2009 Is World Breastfeeding Week
This week long observation of the importance of breastfeeding is organized by the World Breastfeeding Week organization (worldbreastfeedingweek.org). The theme this year is the importance of breastfeeding during emergency situations. It is important that when natural or man-made disasters strike that all involved remember the importance of maintaining and supporting breastfeeding of infants affected by the disaster.
Diagnostics

Merck Seeks European License For Cladribine for relapsing remitting MS

Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington. If the application meets all of the regulatory hurdles, it is set to be the first oral disease modifying drug available to people with MS. If no delays are made, cladribine could be available as early as the middle of 2010, which could mean more choice for people with MS. Multiple Scleroris Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009